Follow Us
© 2026 Arizent. All rights reserved.
Food and Drug Administration Commissioner Marty Makary said he has no plans to change government policy on the abortion pill mifepristone, a hot-button issue in the U.S. since the Supreme Court overturned the landmark Roe v. Wade decision in 2022.
Makary would reconsider the issue if new data emerged that signaled a safety issue with the drug that is now used in more than half of U.S. abortions, he said during an appearance at the Semafor World Economy Summit on Thursday.
For reprint and licensing requests for this article, click here.
Benefit leaders found innovative and cost-effective ways to deal with increasing strain on their healthcare budgets.
Chronic conditions like diabetes, heart disease, cancer, and autoimmune disorders affect more than 60% of Americans —
Novel legal theories and a lower bar for plaintiffs could unleash an explosion in ERISA-based lawsuits against 401(k) plan providers.
Chief strategy officer at MomsRising breaks down how Trump's election may impact access to abortion care nationwide.
There is a powerful relationship between what employees experience in the workplace and their mental health overall.
